Wealthy & Wise: Is P/E Mean Reversion Hitting Top ASX Stocks?

Why It Matters

Recognizing PE mean reversion helps investors differentiate between temporary valuation swings and genuine corporate decline, guiding more informed allocation decisions in Australia’s large‑cap market.

Key Takeaways

• PE mean reversion explains most ASX50 price moves last year.
• High‑PE blue chips suffered larger drops; low‑PE stocks outperformed.
• 45 of 50 ASX50 movements predicted solely by starting PE ratios.
• Distinguishing valuation reset from genuine business decline remains challenging.
• Timing of mean‑reversion depends on catalysts, not just valuation levels.

Summary

Wealthy & Wise examined whether the recent slump in Australia’s top‑cap stocks reflects genuine operational weakness or a simple valuation correction. The hosts focused on price‑to‑earnings (PE) mean reversion – the tendency for a dollar of earnings to command a consistent price over time, regardless of industry – and applied the concept to the ASX50 over the past twelve months.

Using a scatter‑plot of February‑2025 PE levels versus subsequent returns, they found a striking pattern: companies with elevated PEs tended to post negative returns, while low‑PE stocks generated gains. Their statistical model suggested that 45 of the 50 individual stock movements could be explained purely by the starting PE, without invoking sector‑specific news, scandals, or macro‑economic shocks.

Andrew Coleman highlighted concrete examples, noting that ResMed’s 25% decline, CSL’s 55% slide, and WiseTech’s 85% plunge aligned closely with the mean‑reversion forecast. Even firms with headline‑grabbing catalysts, such as healthcare or mining disruptions, largely followed the same trajectory, underscoring the predictive power of the PE metric.

The discussion concluded that while mean‑reversion is inevitable, the timing hinges on external catalysts. For long‑term investors, the correction offers buying opportunities in over‑priced blue chips; for traders, identifying the trigger becomes critical. Understanding whether a price drop signals a valuation reset or a fundamental business deterioration is essential for portfolio allocation and risk management.

Original Description

Some of the ASX’s biggest blue chips have been smashed over the past year.

But are investors witnessing genuine business deterioration or simply valuation gravity pulling prices back to earth?

This week on Wealthy & Wise, we unpack P/E mean reversion, market expectations, and why some of 2026’s so-called “wealth destroyers” may actually be quality companies hiding in plain sight.

We hear from Teaminvest's Andrew Coleman with a special guest appearance from Teaminvest's Peter Hasrouni.

Coleman says since February last year, 25 ASX blue chips have fallen, and four have fallen more than 50%.

Stocks discussed: CSL, Cochlear, ResMed, Pro Medicus, Wesfarmers, WiseTech, and KTEK Aerosystems.